Biologics and other specialised medicines have made a significant improvement in the management of chronic diseases like inflammatory arthritis, inflammatory bowel disease and plaque psoriasis. ​

On this page you will find evidence-based resources to support consumers and health professionals to make safe and wise decisions for using these medicines.

Information and resources

Inflammatory arthritis​

Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis resources

Inflammatory bowel disease

Crohn disease and ulcerative colitis resources

Plaque psoriasis​

Plaque psoriasis resources

for Pharmacists Getty Images-1262625680

For pharmacists

Up-to-date information and resources for pharmacists, to optimise the safety and health outcomes of biologics and other specialised medicines for inflammatory arthritis, inflammatory bowel disease and plaque psoriasis.​

Find out more
Gov-com-Getty Images-1202520728

For medicines governance committees

The Council of Australian Therapeutic Advisory Groups (CATAG) has developed guidance documents to assist good governance and decision-making for health service organisations, medicines governance committees and health professionals.

Find out more

Understanding biologics, their biosimilars and the PBS​

Resources and information to explain how biologics and their biosimilars are approved and funded for use in Australia, and how to talk to your patients about biosimilars.

Find out more

Introducing the Targeted Therapies Alliance

A consortium of organisations working together to help consumers and health professionals make safe and wise decisions about bDMARDs and other specialised medicines.

Value in Prescribing bDMARDs Program and the Targeted Therapies Alliance

NPS MedicineWise former CEO Associate Professor Steve Morris and ARA President and rheumatologist Professor Catherine Hill introduce the bDMARDs program.

TARGETED THERAPIES ALLIANCE

Helping consumers and health professionals make safe and wise therapeutic decisions about biological disease-modifying antirheumatic drugs (bDMARDs) and other specialised medicines. Funded by the Australian Government Department of Health through the Value in Prescribing bDMARDs Program Grant.

The consortium also works closely with the key dermatology and gastroenterology organisations,
The Australasian College of Dermatologists, Psoriasis Australia, Gastroenterological Society of Australia and Crohn’s & Colitis Australia.

TTA consortium organizations